行情

CBAY

CBAY

CymaBay
NASDAQ

实时行情|Nasdaq Last Sale

5.75
-0.26
-4.33%
盘后: 5.75 0 0.00% 16:32 09/13 EDT
开盘
6.08
昨收
6.01
最高
6.19
最低
5.74
成交量
73.69万
成交额
--
52周最高
14.00
52周最低
4.820
市值
3.95亿
市盈率(TTM)
-4.2162
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBAY 新闻

  • 绝不延迟脱欧 英首相自比"绿巨人":越疯狂,就越强大
  • 环球网.1小时前
  • 沙特石油设施遇袭产量减半 美随时准备动用石油储备
  • 新京报网.2小时前
  • 新华国际时评:央行“放水”恐难纾欧元区之困
  • 新华网.2小时前
  • 沙特官员:周一石油产量将恢复到正常水平
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

CBAY 简况

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
展开

Webull提供CymaBay Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。